Plus de 40 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Pleiotropic treatment of cancer: RANK inhibitors targeting cancer stem cells and immunity (PLEIO-RANK)
Date du début: 1 oct. 2016, Date de fin: 30 sept. 2021,
"Thousands of cancer patients worldwide are taking RANKL inhibitors for the management of bone metastasis, based on the key role of RANKL and its receptor, RANK, in osteoclasts. RANK signaling has multiple divergent effects in immunity and inflammation, both in the generation of active immune responses, as well as in the induction of tolerance. We showed that RANK overexpression induces stemness a ...
Voir le projet
1
Participant partenaire
TERMINÉ
Deciphering PI3K biology in health and disease (Phd)
Date du début: 1 nov. 2015, Date de fin: 31 oct. 2019,
The Phosphoinositide 3-kinase (PI3K) pathway is at the core of multiple fundamental biological processes controlling metabolism, protein synthesis, cell growth, survival, and migration. This inevitably leads to the involvement of the PI3K signalling pathway in a number of different diseases, ranging from inflammation and diabetes to cancer, with PI3K pathway alterations present in almost 80% of hu ...
Voir le projet
11
Participants partenaires
TERMINÉ
Endoplasmic Reticulum Stress in Health and Disease (TRAIN-ERS)
Date du début: 1 oct. 2015, Date de fin: 30 sept. 2019,
Endoplasmic reticulum (ER) stress is emerging as a common feature in the pathology of numerous diseases including cancer, neurodegenerative disorders, metabolic syndromes and inflammatory diseases. Thus ER stress represents a potential therapeutic intervention point to be exploited to develop novel therapies, diagnostic tools and markers for these diseases. However, exploitation is hampered by the ...
Voir le projet
12
Participants partenaires
TERMINÉ
Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases (PRECISESADS)
Date du début: 1 févr. 2014, Date de fin: 31 janv. 2019,
We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therape ...
Voir le projet
30
Participants partenaires
TERMINÉ
Chromatin Dynamics in Development and Disease (Chromatin3D)
Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,
The cell nucleus is organized and compartmentalized into a highly ordered structure that contains DNA, RNA, chromosomal and histone proteins which make up a structure called chromatin. The dynamics associated with these various components are responsible for regulating physiological processes and the overall stability of the genome. The destabilization of such regulatory mechanisms that act on the ...
Voir le projet
12
Participants partenaires
TERMINÉ
Development of a ncRNA DNA Methylation Kit for Treatment Guidance in Cancer of Unknown Primary (EPIPHARM)
Date du début: 1 févr. 2017, Date de fin: 31 juil. 2018,
The innovative idea behind the EPIPHARM (EPIgenetics of PHARMacogenetics) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify a drug sensitivity fingerprint based in the DNA methylation profile of non-coding RNA (ncRNA) loci. CUPs are a heterogeneous group of cancers defined by the presence of metasta ...
Voir le projet
1
Participant partenaire
TERMINÉ
Identification and Characterization of Cis-Regulatory ModuleDysfunction in Rett Syndrome with ROQ-WACh (ROQ-WACh)
Date du début: 1 mars 2016, Date de fin: 28 févr. 2018,
Precise regulation of gene expression is achieved through the coordinated action of genomic cis-regulatory modules (CRMs). The identification of CRMs has long been a goal of functional genomics as CRM dysregulation can have devastating consequences for health and development such as autism. For example, mutations in the MeCP2 gene, which encodes protein that binds methylated DNA and regulates gene ...
Voir le projet
1
Participant partenaire
TERMINÉ
Defining the role of xeno-directed and autoimmune events in patients receiving animal-derived bioprosthetic heart valves (TRANSLINK)
Date du début: 1 sept. 2013, Date de fin: 31 août 2017,
TRANSLINK is a project devoted to assessing the mid-to long-term risk factors and improve the outcome of animal (bovine/porcine)-derived Bioprosthetic Heart Valve (BHV) implants. 300,000 patients/year benefit from BHV, a major healthcare problem (second most frequent cardiac surgery). BHV clinical outcome suffers from late dysfunctions restricting their application to older recipients. Based on a ...
Voir le projet
14
Participants partenaires
TERMINÉ
Crosstalk between microRNAs and epigenetics in melanocyte differentiation: A new approach to unravel the complexity of melanoma progression and metastasis (EPIMIRMEL)
Date du début: 23 avr. 2014, Date de fin: 1 juil. 2017,
Melanoma is the most aggressive form of skin cancer and one of the most invasive tumor types. Melanoma incidence keeps increasing worldwide and the therapeutic choices are limited. The lack of treatments with durable responses may be due, at least in part, to an incomplete understanding of the molecular mechanisms that regulate tumor initiation and/or progression to metastasis. Therefore, there is ...
Voir le projet
1
Participant partenaire
TERMINÉ
Epigenetic Training Network - Innovative techniques and models to understand epigenetic regulation in the pathogenesis of common diseases (EPITRAIN)
Date du début: 1 mars 2013, Date de fin: 28 févr. 2017,
"Despite the past century witnessing considerable advances in our understanding of genetics, the success of genome-wide association studies (GWAS) in detecting putative causal variants has been tinged with disappointment as the effects found have been modest. Epigenetics promises a novel biological foundation of a new way of looking at common diseases because it responds to the environment and gov ...
Voir le projet
6
Participants partenaires
TERMINÉ
Vascular Endothelial interactionS and SpEciaLization (Vessel)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,
The vascular network plays essential roles in animal biology. Local disruption or impaired function of the vascular network is known to cause various pathological conditions, such as ischemic heart disease and stroke. The angiogenic growth of blood vessels is critically required during development, growth and regeneration, but it can also promote the growth of cancer cells and contribute to diabet ...
Voir le projet
9
Participants partenaires
TERMINÉ
STRATEGY TO INHIBIT TGF-Beta IN LIVER DISEASE (IT-LIVER)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,
Chronic liver diseases (CLD) and their end-stages, cirrhosis and hepatocellular carcinoma (HCC), are leading causes of morbidity and mortality worldwide with enormous socio-economic costs. Patients with liver cirrhosis are at high risk of deadly hepatic failure and over 80% of HCC develop on a cirrhotic background. HCC ranks as the 5th most common cancer and with >600,000 deaths per annum it const ...
Voir le projet
12
Participants partenaires
TERMINÉ
A BLUEPRINT of Haematopoietic Epigenomes (BLUEPRINT)
Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,
In response to the call for a high impact initiative on the human epigenome, the BLUEPRINT Consortium has been formed with the aim of generating at least 100 reference epigenomes and studying them to advance and exploit knowledge of the underlying biological processes and mechanisms in health and disease. BLUEPRINT will focus on distinct types of haematopoietic cells from healthy individuals and o ...
Voir le projet
45
Participants partenaires
TERMINÉ
European collaborative project on Targeted therapy in renal cell cancer: genetic and tumor-related biomarkers for response and toxicity (EuroTARGET)
Date du début: 1 mars 2011, Date de fin: 31 août 2016,
Each year more than 63,000 new cases of kidney cancer are diagnosed in the European Union. Approx. 50% of all patients have metastasized renal cell cancer (mRCC) at presentation or develop metastases during follow-up. 5-year relative survival of mRCC has been extremely poor: between 5 and 10%. In the past few years, so-called targeted therapies that suppress angiogenesis have changed the clinical ...
Voir le projet
15
Participants partenaires
TERMINÉ
ADenoViruses as novel clinical treatments (ADVANCE)
Date du début: 1 avr. 2012, Date de fin: 31 mars 2016,
ADVance is designed to integrate 8 leading academic centres and 4 private companies under a single umbrella to create an opportunity to train young scientists in adenovirus (AdV) research. Our full partners and industrial partners represent internationally leading academic centres of excellence in key facets of research into the basic biology of AdV and their application as vectors for clinical p ...
Voir le projet
13
Participants partenaires
TERMINÉ
Epigenetic Disruption of Non-Coding RNAs in Human Cancer (EPINORC)
Date du début: 1 avr. 2011, Date de fin: 31 mars 2016,
In recent years, my laboratory, as well as others, have established the observation that epigenetic disruption, particularly in the DNA methylation and histone modification patterns, contributes to the initiation and progression of human tumors (Esteller, Nat Rev Genet 2007; Esteller, N Engl J Med 2008; Esteller, Nat Rev Biotech, In Press, 2010). Even more recently, it has been recognized that mic ...
Voir le projet
1
Participant partenaire
TERMINÉ
The Role of the RPL11/p53 Checkpoint in the Development and Treatment of DBA (DBA-Checkpoints)
Date du début: 1 mars 2012, Date de fin: 29 févr. 2016,
Extensive studies have demonstrated that the underlying cause of Diamond Blackfan anemia (DBA) is hypomorphic mutations in ribosomal protein (rp) genes. Patients with this disease present with an erythroid anemia, which has the propensity to progress to a wide range of cancers, particularly acute myeloid leukemia and osteosarcomas. Recently our laboratory has provided a model to explain the anemia ...
Voir le projet
1
Participant partenaire
TERMINÉ
Development of a ncRNA DNA Methylation Kit for the Diagnosis of Cancer of Unknown Primary (EPICUP)
Date du début: 1 févr. 2015, Date de fin: 31 janv. 2016,
The innovative idea behind the EPICUP (EPIgenetics of Cancer of Unknown Primary) project is to develop a package demonstrating the feasibility of a high-throughput tool for epigenotyping Cancer of Unknown Primary (CUP) to identify tumor type based in the DNA methylation profile of non-coding RNA (ncRNA) loci. CUPs are a heterogeneous group of cancers defined by the presence of metastatic disease w ...
Voir le projet
1
Participant partenaire
TERMINÉ
Modulation of AMPA receptor properties by auxiliary subunits (MOAMAUX)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
AMPA-type glutamate receptors (AMPARs) mediate most fast excitatory synaptic transmission in the brain. The regulation of certain AMPARs (calcium-permeable; CP-AMPARs) is relevant in synaptic plasticity, neuronal development and certain neurological diseases. AMPARs are regulated by transmembrane AMPA regulatory proteins (γ-2, -3, -4, -8; TARPs), which affect the trafficking and also important bio ...
Voir le projet
1
Participant partenaire
TERMINÉ
Mechanisms of prevention of type 2 diabetes by lifestyle intervention in subjects with pre-diabetes or at high-risk for progression (DEXLIFE)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2015,
"Type 2 diabetes (T2DM) is preventable by sustained changes in diet and physical exercise. Despite this, modern societies are already approaching 10% population prevalence of diabetes, and another 15% with pre-diabetes. The costs of T2DM are huge, approaching 10% of all health costs. Prevention of diabetes is a priority for national healthcare agencies and for the health insurance industry. Inve ...
Voir le projet
12
Participants partenaires
TERMINÉ
Systems Biology of Colorectal Cancer (SYSCOL)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,
Colorectal cancer (CRC) is one of the most common cancers in both males and females, and it is perhaps the best understood of all epithelial tumors in terms of its molecular origin. Yet, despite large amount of work that has concentrated on understanding of colon tumorigenesis, we still do not know the full complement of molecular lesions that are individually necessary – and together sufficient – ...
Voir le projet
11
Participants partenaires
TERMINÉ
User-driven Development of Statistical Methods for Experimental Planning, Data Gathering, and Integrative Analysis of Next Generation Sequencing, Proteomics and Metabolomics data (STATegra)
Date du début: 1 oct. 2012, Date de fin: 30 sept. 2015,
Users of NGS technologies, producing large and numerous distinct types of omics data, demands statistical methods to combat data and knowledge fragmentation and inappropriate procedures for data analysis. Yet, the current a gap between the available tools for analysis of a single omics data-type versus the requirement of biomedical scientists to understand the integrated results derived from sever ...
Voir le projet
11
Participants partenaires
TERMINÉ
Role of human papillomavirus infection and other co-factors in the aetiology of head and neck cancer in India and Europe (HPV-AHEAD)
Date du début: 1 sept. 2011, Date de fin: 31 août 2015,
Human papillomavirus (HPV) is responsible for approximately 25% of head and neck cancer (HNC) worldwide and appears to be associated with a better response to treatment and improved prognosis. Evidence suggests that HPV-induced HNC has steadily increased in the USA and some European countries in the last decades. However, whether this is a worldwide phenomenon and specific risk factors are associa ...
Voir le projet
11
Participants partenaires
TERMINÉ
Use of adoptive T cell transfer in combination with oncolytic adenoviruses for cancer treatment (Cancer therapies)
Date du début: 1 mai 2011, Date de fin: 31 août 2015,
Metastatic cancer remains an incurable disease in the majority of cases and thus development of novel treatment strategies is required. Adoptive T cell therapy is a promising therapy for patients with a wide range of cancers. This therapy involves ex vivo activation and expansion of T cells followed by infusion into patients. Peripheral blood CD4+ and CD8+ T cells can be redirected against tumor-a ...
Voir le projet
2
Participants partenaires
TERMINÉ
Systems biology towards novel chronic kidney disease diagnosis and treatment (SysKID)
Date du début: 1 janv. 2010, Date de fin: 31 déc. 2014,
Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal disease CKD impacts the patient’s quality of life by causing serious comorbidities including cardiovascular complications and bone metabolism disorders. On the everyday clinical level early stage diagnosis and tailored treatment of CKD are still inadequate. In addition, CKD seems ...
Voir le projet
30
Participants partenaires
TERMINÉ
Modelling and predicting sensitivity to targeted therapies in colorectal cancers (COLTHERES)
Date du début: 1 janv. 2011, Date de fin: 31 déc. 2014,
Effective and long term treatment of cancer is now in sight, but will ultimately require an increasingly ‘personalised’ approach where the ‘right’ combination of drugs will be administered to the ‘right’ patients, based on a detailed understanding of their genetic background and their co-associated sensitivity or resistance ‘biomarkers’. Efforts are specifically required to identify validated risk ...
Voir le projet
11
Participants partenaires
TERMINÉ
Pathways common to brain development and ageing: defining strategies for preventive therapy and diagnostics (DEVELAGE)
Date du début: 1 janv. 2012, Date de fin: 31 déc. 2014,
"The increasing number of elderly people will have a major impact on the prevalence of age-related diseases, which will pose major challenges to keep health systems in Europe sustainable. Current knowledge is insufficient to identify the transition of normal brain ageing into Alzheimer`s Disease (AD)-like brain damage. Elucidation of the genes and pathways contributing to the earliest stages of AD ...
Voir le projet
9
Participants partenaires
TERMINÉ
Development of OPN-305 as an orphan drug for the treatment of Delayed Graft Function post solid organ transplantation (MABSOT)
Date du début: 1 déc. 2010, Date de fin: 30 sept. 2014,
Delayed graft function (DGF) is defined as the need for dialysis within seven days of renal transplantation (DGF promotes allograft rejection, requires prolonged dialysis and hospitalisation, and increases the likelihood of graft failure and ultimately the duration of renal graft survival-expectancy. The incidence of DGF occurs in 21-44% of cases following cadaveric renal graft. Several rare dise ...
Voir le projet
10
Participants partenaires
TERMINÉ
Immunomodulatory Effects of Exercise in Type 1 Diabetes (IMMEEDIA)
Date du début: 1 juil. 2010, Date de fin: 30 juin 2014,
"Diabetes is a major metabolic disease with huge costs for healthcare system throughout the EU and worldwide. Type 1 Diabetes (T1DM) is a chronic condition in which pancreas produces little or no insulin, believed to result from a disorder of immunoregulation. For decades it has been known that regular aerobic exercise improves insulin sensitivity in diabetic patients, reducing insulin requirement ...
Voir le projet
5
Participants partenaires
TERMINÉ
Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis (CURELUNG)
Date du début: 1 janv. 2011, Date de fin: 30 juin 2014,
"Lung cancer (LC) is still the most lethal type of cancer worldwide. The extremely poor prognosis for LC patients is partly due to the lack of effective therapies. At present, most patients with pulmonary carcinomas are treated with chemotherapy. This essentially consists of classic cytotoxic drugs which only improve survival in small cohorts in few cases. In spite of the rapidly growing understan ...
Voir le projet
11
Participants partenaires
TERMINÉ
Genomic predictors and oncogenic drivers in hepatocellular carcinoma (HEPTROMIC)
Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,
"Hepatocellular carcinoma (HCC) accounts for more than 90% of liver cancers, and is a major health problem. Its incidence is growing and with more than 700,000 annual cases worldwide -50,000 in Europe-, it is the 3rd cause of cancer-related mortality. Most patients are diagnosed at advanced stages with dismal survival rates lower than 1 year, even after sorafenib, the sole systemic therapy availab ...
Voir le projet
10
Participants partenaires
TERMINÉ
Chromatin diseases: from basic mechanisms to therapy (DisChrom)
Date du début: 1 nov. 2009, Date de fin: 31 oct. 2013,
The scope of this ITN is to promote research and training in the field of chromatin diseases. Chromatin diseases (CD) are genetic pathologies resulting from mutations in structural components of chromatin or in enzymes that biochemically modify chromatin, altering chromatin status and thereby causing drastic effects on gene expression. CD frequency ranges from very rare to quite common pathologies ...
Voir le projet
11
Participants partenaires
TERMINÉ
Therapeutic challenge in Leukodystrophies: Translational and ethical research towards clinical trials (LEUKOTREAT)
Date du début: 1 mars 2010, Date de fin: 31 août 2013,
Leukodystrophies (LDs) are inherited rare neurodegenerative diseases of the white matter and its main component, the myelin, that are affecting predominantly children. Severity of the disease is related to the axonal dysfunction due to myelin deficiency or destruction. Despite the achievement of remarkable advances made in the past decade, there is no current curative therapy. The development of t ...
Voir le projet
25
Participants partenaires
TERMINÉ
Assembly of a prostate cancer genome-wide molecular interactome for the identification of the key regulatory genes of malignant transformation and new targets for therapeutic intervention (PC interactome)
Date du début: 2 août 2010, Date de fin: 14 août 2013,
A major issue in the translation of findings from mouse models to clinical practice is the lack of appropriate tools to identify causal mechanisms of oncogenesis, tumor progression, and drug activity. The multidisciplinary project here proposed will characterize fundamental mechanisms and signaling pathways deregulated in prostate cancer through the assembly of a prostate cancer interactome, which ...
Voir le projet
1
Participant partenaire
TERMINÉ
health-economic modelling of PREvention strategies for Hpv-related Diseases in European CounTries (PREHDICT)
Date du début: 1 mai 2010, Date de fin: 30 avr. 2013,
"The goals of the PREHDICT study are to determine prerequisites and strategies for vaccination in European countries and to predict the impact of vaccination on screening programmes. To achieve these goals, a multiple HPV type transmission model will be built to describe the type-specific incidence and clearance of HPV infections. This model will be linked to an individual-based simulation model u ...
Voir le projet
14
Participants partenaires
TERMINÉ
Breaking Tolerance - Combination of Virotherapy and Immunotherapy for Cancer Treatment (Viral&Immune Therapy)
Date du début: 1 févr. 2011, Date de fin: 31 janv. 2013,
The aim of this project is to enhance the efficacy of a tumour killing virus and break tolerance within the tumour to induce an immune response against the primary tumour and metastatic deposits. The proposed strategy requires three steps. First, the tumour immunological microenvironment needs to be reset as tumours utilize a variety of mechanisms to escape host immune system. Here, we propose to ...
Voir le projet
1
Participant partenaire
TERMINÉ
Modelling cancer in Caenorhabditis elegans (canceromics)
Date du début: 1 oct. 2007, Date de fin: 31 mars 2012,
Cancer is a complex disease that results from accumulation of diverse alterations in the genome. There are more than 300 genes identified as “cancer genes” although it is estimated that there are many more involved in cancer development that could be significant during tumorigenesis and putative targets for drugs therapies. Several scientific groups are performing a comprehensive sequencing of gen ...
Voir le projet
2
Participants partenaires
TERMINÉ
Cellular and molecular mechanisms of the light response in photoreceptor cells of the mammalian retina (RODCELL)
Date du début: 1 janv. 2008, Date de fin: 31 déc. 2011,
"Genetic defects in proteins involved in the transduction of light in photoreceptor cells of the retina lead to severe retinal degenerations and blindness. Mutations that primarily affect rod function lead to retinitis pigmentosas. These diseases affect 1 in 4000 individuals, initially causing night blindness. As the gradual loss of rods eventually compromises cone cell viability, they lead to ...
Voir le projet
1
Participant partenaire
TERMINÉ
Role of Class IIa Histone deacetylases in hematopoietic cell differentiation (HDAC hematopoiesis)
Date du début: 1 sept. 2007, Date de fin: 31 août 2011,
Chromatin, the higher order structure of DNA and protein, forms a barrier for gene transcription. Modification of histones, a major component of the chromatin, is a critical mechanism by which the barrier is regulated. An important modification, which is thought to activate transcription, is the acetylation of histones. Regulation of histones acetylation is performed by the antagonistic activiti ...
Voir le projet
2
Participants partenaires
TERMINÉ
The use of Methylated DNA Immunoprecipitation MeDIP in cancer for better clinical management (CANCERDIP)
Date du début: 1 janv. 2008, Date de fin: 30 juin 2011,
"Aberrant DNA methylation is the most common molecular lesion of the cancer cell. Neither gene mutation nor cytogenetic abnormalities are as common in human tumours as DNA methylation alterations. The stability of our genome and correct gene expression is maintained to a great extent thanks to a perfectly preestablished pattern of DNA methylation and histone modifications. In cancer this idealisti ...
Voir le projet